deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT03364686

Transfusion of Biotin-Labeled Red Blood Cells

Transfusion of Biotin-Labeled Red Blood Cells for the Evaluation of Genetic Factors That Contribute to Donor Differences in Red Blood Cell Storage and Post-Transfusion Red Blood Cell Recovery

Sponsor: Gladwin, Mark, MD

Conditions Healthy Volunteers
Interventions Biotin-Labeled Red Blood Cells
Updated 19 times since 2017 Last updated: Mar 29, 2022 Started: Sep 16, 2019 Primary completion: Mar 2, 2021 Completion: Jun 29, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to enrollment challenges related to COVID and lack of coordinator support

Other terminated trials from Gladwin, Mark, MD

See all terminations from Gladwin, Mark, MD

Other Healthy Volunteers trials with similar outcome

Browse all Healthy Volunteers trials

This PHASE2 trial investigates Healthy Volunteers and is currently terminated or withdrawn. Gladwin, Mark, MD leads this study, which shows 19 recorded versions since 2019 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Dec 2017 – ~May 2018 · 5 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jan 2019 · 3 months · monthly snapshot~Jan 2019 – ~Mar 2019 · 59 days · monthly snapshot~Mar 2019 – ~Apr 2019 · 31 days · monthly snapshot~Apr 2019 – ~Jun 2019 · 2 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~May 2020 · 6 months · monthly snapshot~May 2020 – ~Jul 2020 · 2 months · monthly snapshot~Jul 2020 – ~Jan 2021 · 6 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Sep 2021 · 5 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Terminated PHASE2

    Status: Completed → Terminated

  4. Sep 2021 — May 2022 [monthly]

    Completed PHASE2

    Status: Recruiting → Completed

  5. Apr 2021 — Sep 2021 [monthly]

    Recruiting PHASE2

▶ Show 14 earlier versions

  1. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  2. Jul 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  3. May 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

  4. Nov 2019 — May 2020 [monthly]

    Recruiting PHASE2

  5. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE2

  6. Jul 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

  7. Jun 2019 — Jul 2019 [monthly]

    Recruiting PHASE2

  8. Apr 2019 — Jun 2019 [monthly]

    Recruiting PHASE2

  9. Mar 2019 — Apr 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jan 2019 — Mar 2019 [monthly]

    Not Yet Recruiting PHASE2

  11. Oct 2018 — Jan 2019 [monthly]

    Not Yet Recruiting PHASE2

  12. Jun 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE2

  13. May 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

  14. Dec 2017 — May 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gladwin, Mark, MD
  • National Heart, Lung, and Blood Institute (NHLBI)
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations